The global Oral Controlled Release Drug Delivery Technology Market is poised to grow from USD 34.1 billion in 2022 to USD 68.4 billion by 2032, with overall demand expected to surge at 7.2% CAGR throughout the forecast period (2022 to 2032).
The rising incidence of chronic diseases coupled with a growing preference for oral drug delivery due to its various benefits is the key factor driving demand for oral controlled-release drug delivery technology.
Based on form, the solid dosage forms segment is expected to lead the global oral controlled release drug delivery technology market throughout the forecast period with an estimated share of nearly 87%.
| Attribute | Key Statistics |
|---|---|
| Oral Controlled Release Drug Delivery Technology Market Base Value (2021) | USD 31.8 billion |
| Estimated Market Value (2022) | USD 34.1 billion |
| Projected Market Value (2032) | USD 68.4 billion |
| Value-based CAGR (2022 to 2032) | 7.2% |
| Market share of Top 5 countries | 62.1% |
The oral controlled release drug delivery system is designed to deliver a drug in a controlled and predictable manner over a period of time or at a predetermined position in the gastrointestinal tract. Oral dosage forms are preferred for their convenience and cost-effectiveness.
Oral controlled release drug delivery technologies like, Geolock, Geomatrix, OROS (osmotic-controlled release drug delivery system), SODAS (Spheroidal oral drug absorption system), and many more are exclusively used for most of the pharmaceutical drug candidates and are the most common form to deliver medication to patients.
Oral solid dosage forms coupled with new drug releases mechanisms such as dissolution and diffusion-controlled drug release delivery systems are expected to remain a mainstay in the global pharmaceuticals market as these type of new and enhanced drug delivery systems with the use of advanced polymers tend to be an important part of drug development technology and approvals of new chemical entities.
The overall oral controlled release drug delivery technology market formed nearly 14% of the global pharmaceutical drug delivery market which was valued at around USD 230 billion in 2021
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales in the oral controlled release drug delivery technology market are projected to rise at 7.2% CAGR during the forecast period between 2022 to 2032, in comparison to 6.5% CAGR registered from 2012 to 2021.
Growing demand for specialized oral dosage forms such as pediatric or geriatric tablets with controlled release drug delivery systems, the adoption rate of newly developed and innovative technologies such as nanotechnology, osmotically controlled release, hydrophilic ion exchange, etc. are the prime factors expected to drive the growth of oral controlled release drug delivery technology market over the forecast period.
Oral drug delivery has become the most preferred and convenient option as the oral route provides maximum active surface area among all drug delivery systems for the administration of various drugs.
Increasing generic penetration is another important factor pushing the growth of the global market. Oral solid dosage forms such as tablets and capsules represent the largest growth opportunity for generic players.
Some other factors influencing the growth of the global oral controlled release drug delivery technology market include cost-effective generic dosage forms, Research and Development (R&D) scientists, and healthcare professionals’ preference for sustained release controlled delivery coupled with new biopolymers embedded with advanced coating technology in solid dosage forms, liquids, and semisolids.
Furthermore, the combination of various technologies to overcome the limitations of poorly soluble substances/drugs/chemicals and the higher adoption rate of these combined products/technologies at convenient pricing is expected to boost the oral controlled release drug delivery technology market.
In addition to this, increasing approval of modified and extended-release oral dosage forms by various health ministries across the world is likely to drive the market.
The rise in Chronic Diseases and Advancement in Drug Delivery Techniques to Boost Market Growth
As per FMI, the global oral controlled release drug delivery technology market is projected to expand at a robust pace during the forecast period, owing to the rising prevalence of chronic and infectious diseases like cancer, T.B. heart disease, diabetes, etc., and increasing spending on oral medications.
Similarly, continuous efforts of manufacturers to develop and produce novel complex drug products with customized release trends will propel the expansion of the oral controlled release drug delivery technology market globally during the forecast years.
Use of combination techniques such as modified controlled release mechanisms and other platforms which uses ion exchange release (hydrophilic & hydrophobic), osmotically controlled release, diffusion & dissolution (combined) controlled release in new drug formulation procedures is on the rise across the healthcare industry and the trend is likely to continue during the forecast period.
Also, the introduction of super generics, continuous new technology launches, and a growing number of contract manufacturing facilities for oral solid dosage forms & liquid dosage forms, and enhanced patient compliance are expected to create lucrative market growth opportunities during the forecast period.
According to research published in the Journal of Controlled Release, it has been found that ‘casein’ based formulations are probable contenders for controlled release drug delivery systems, because of their properties like high tensile strength and presence of naturally occurring genipin, tissue enzyme & transglutaminase.
Casein can also be used as a cross-linkers to prepare novel casein-based hydrogels for the controlled release of bioactive.
Similarly, the growing usage of 3D printing technology for designing and manufacturing oral formulations is expected to create lucrative opportunities for oral controlled-release drug delivery system manufacturers.
3D printing techniques can be used to produce multiple doses of drugs at a small scale and to improve drug formulations. 3D printing technology can be a great prospect for manufacturers to impose in their innovative, research and development department for drug formulations.
Principal Consultant
Formulation challenges are mainly drug-related - active pharmaceutical ingredients with a short half-life and the necessity for higher-dose delivery and formulation related, which regularly require dissolvable handling capacities in light of the fact that most polymers should be solubilized in natural solvents before covering the controlled-release formulations (i.e., tablets, granules, and capsules)
Growing research towards biological molecules and their dominance in treating oncology conditions are expected to hamper the growth of the oral controlled release drug delivery technology market over the forecast period.
According to an article published in Contract pharma, approximately 50% of the pipeline molecules are biologics and the rest are in the form of other dosage forms.
However, the low pipeline productivity of oral solids is the major factor hindering the growth of the oral controlled-release drug delivery technology market.
Other factors include a complex supply chain and stringent regulatory requirements, decreasing productivity coupled with low R&D expenditure, product related issues such as dose dumping and product recalls.
Rising Spending on Medicines Fuelling Market Growth in the USA
The USA oral controlled release drug delivery technology market reached a valuation of over USD 11.0 billion in 2021 and is expected to grow over a CAGR of 7.0% during the forecast period (2022 to 2032).
The rising prevalence of chronic diseases such as cancer and diabetes, supporting initiatives & campaigns from the government, and investments in research & development are driving b growth in the USA market and the trend is likely to continue during the forecast period.
Similarly, the strong presence of major key players in the country and their promotional strategies for the adoption of controlled release drug delivery systems are expected to expand the oral controlled release drug delivery technology market in the future.
In addition to this, increasing spending on medicines across the country will create opportunities for oral controlled-release drug delivery technology manufacturers in the future. In fact, the USA is the highest spending country worldwide when it comes to health care.
According to the USA Department of Health and Human Services, USA prescription drug expenditures totaled an enormous valuation of USD370 billion in 2019 and this number is likely to further surge during the assessment period.
Rising Prevalence of Heart Diseases Driving Demand Across Germany
As of 2021, Germany held a revenue share of 21.5% of total European oral controlled release drug delivery technology market and it is estimated to grow at a healthy pace during the forecast period.
The German oral controlled release drug delivery technology market will likely be driven by improved patient compliance, rising geriatric and paediatric populations, and increased demand for controlled release drug delivery systems due to the prevalence of chronic diseases.
Over the years, there has been a sharp rise in cases of heart disease across Germany leading to a high death rate. Oral solid dosages are utilized very commonly for the treatment of the same. As per the World Health Organization (WHO) insights in 2019, nearly 37% of deaths in Germany were due to circulatory diseases.
Thus, the growing demand for oral solid dosage together with the rising prevalence of circulatory disease is expected to boost Germany’s oral controlled release drug delivery technology market during the next ten years.
Growing Preference for Oral Medication Fostering Market Growth in Japan
The overall oral controlled release drug delivery technology market in Japan reached USD 2.6 billion in 2021 and it is expected to expand at a CAGR of around 6.7% during the forecast period.
This can be attributed to the rising popularity of oral medication among the country’s rapidly growing population, advancements in the pharmaceutical sector, and increasing investments in R&D activities by biopharma companies.
Similarly, increasing healthcare spending and high levels of health awareness among the general public are expected to bolster the growth of the oral controlled release drug delivery technology market in Japan during the forthcoming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand Remains High for Dissolution Controlled Release System
The dissolution controlled release system segment dominated the global oral controlled release drug delivery technology market with a revenue share of nearly 45% in 2021 and the trend is projected to continue throughout the forecast period.
Properties such as maximum efficacy with minimal side effects and reduced drug accumulation with drug level fluctuation are the major reasons for the adoption of this technique.
The dissolution controlled release system provides sustained release profiles i.e., In a dissolution controlled release system, the active drugs are released continuously at a slow rate to provide a long-term therapeutic effect. Thus, they provide a sustained release profile, which is encouraging their adoption across the world.
End Users Prefer Solid Dosage Forms
As per FMI, the solid dosage forms segment generated revenue of around USD 27 billion in the global oral controlled release drug delivery technology market in 2021 and it is poised to grow at a higher CAGR over the next ten years. This can be attributed to the rising end-user preference for solid dosage forms.
Owing to the better physical and chemical stability, lower manufacturing costs, and easy-to-consume & carry features of solid dosage forms, it remains highly popular among end users. People are increasingly opting for solid dosage forms like tablets, capsules, and powders to treat various diseases.
Some of the key players identified in global oral controlled release drug delivery technology market are AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., F. Hoffman-La-Roche Ltd., and Johnson & Johnson.
These players are trying to combine new molecular entities with existing ones to explore clinical indications for controlled release mechanisms, which in turn is propelling the discovery of new matrix systems in the oral controlled release drug delivery technology market. Furthermore, they are partnering and collaborating with other companies to increase their revenue share. For instance,
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | USD 34.1 billion |
| Projected Market Size (2032) | USD 68.4 billion |
| Anticipated Growth Rate (2022 to 2032) | 7.2% |
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, the Rest of Latin America, The United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, the Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Australia, New Zealand, Turkey, GCC, South Africa, Israel, North Africa and Rest of MEA. |
| Key Market Segments Covered | Drug Release System, Dosage Form, Region |
| Key Companies Profiled | AstraZeneca Plc.; Bristol-Myers Squibb Company; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; F. Hoffman-La-Roche Ltd.; Johnson & Johnson; GlaxoSmithKline Plc.; Sun Pharmaceuticals; Sanofi S.A.; Boehringer Ingelheim; AbbVie; Takeda; Eli Lilly; Bayer; Gilead Sciences; Amgen; BioNTech; Viatris; Moderna. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The global oral controlled release drug delivery technology market is estimated to be valued at USD 34.1 billion in 2022.
The global oral controlled release drug delivery technology market is anticipated to reach a valuation of about USD 68.4 billion by the end of 2032.
As per FMI, the global oral controlled release drug delivery technology market is expected to grow at around 7.2% CAGR during the forecast period.
North America will continue to dominate the global oral controlled release drug delivery technology, exhibiting a growth rate of 6.9% CAGR throughout the forecast period.
With a valuation of nearly USD 27 Billion in 2021, the solid dosage forms segment will continue to lead the global oral controlled release drug delivery technology market.
AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., F. Hoffman-La-Roche Ltd., Johnson & Johnson, GlaxoSmithKline Plc., and Sun Pharmaceuticals are the major players operating in the global market.
Increasing adoption rates of the newer technologies, growing incidence of chronic diseases, increasing geriatric & paediatric population, and investments in research & development activities are some of the major factors driving the global oral controlled release drug delivery technology market.
1. Executive Summary | Oral Controlled Release Drug Delivery Technology Market 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Oral Controlled Release Drug Delivery Technology Market Demand (in Value) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7. Global Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release System 7.1. Dissolution Controlled Release System 7.2. Diffusion Controlled Release System 7.3. Osmotically Controlled Release System 7.4. Dissolution & Diffusion Controlled Release System 7.5. Ion Exchange Resins Controlled Release 7.6. Hydrodynamically Balanced Drug Delivery System 7.7. Others 8. Global Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form 8.1. Solid Dosage Form 8.2. Semisolid/Liquid/Suspensions 9. Global Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. East Asia 9.5. South Asia 9.6. Oceania 9.7. Middle East and Africa (MEA) 10. North America Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032 11. Latin America Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032 12. Europe Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13. East Asia Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14. South Asia Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15. Oceania Oral Controlled Release Drug Delivery Technology Market 2012-2021 and Forecast 2022-2032 16. Middle East and Africa (MEA) Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17. Market Structure Analysis 18. Competition Analysis 18.1. AstraZeneca Plc. 18.2. Bristol-Myers Squibb Company 18.3. Merck & Co. Inc. 18.4. Novartis AG 18.5. Pfizer Inc. 18.6. F. Hoffman-La-Roche Ltd. 18.7. Johnson & Johnson 18.8. GlaxoSmithKline Plc. 18.9. Sun Pharmaceuticals 18.10. Sanofi S.A. 18.11. Boehringer Ingelheim 18.12. AbbVie 18.13. Takeda 18.14. Eli Lilly 18.15. Bayer 18.16. Gilead Sciences 18.17. Amgen 18.18. BioNTech 18.19. Viatris 18.20. Moderna 19. Assumptions and Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Oral Controlled Release Drug Delivery Technology Market
